SecBot SecBot
PRESS-RELEASE ·Filed Apr 15, 2026

XENE

Xenon Pharmaceuticals Inc.
BEARISH
Impact 5/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Traders should anticipate continued negative sentiment due to the earnings miss; absence of financial detail in a so-called 'earnings release' raises transparency concerns. Monitor upcoming conference presentations for potential data updates.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$58.88
T+0 close · Apr 15, 2026 · via day close
Latest settled
+17.05%
T+60 · $68.92
Vs SPY
+8.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 15 $58.88entry
  2. T+1 · 7mo ago −0.76%α −1.02% · $58.43
  3. T+5 · 7mo ago −3.79%α −5.43% · $56.65
  4. T+20 · 6mo ago −6.59%α −12.63% · $55.00
  5. T+60 · 4mo ago +17.05%α +8.91% · $68.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon Pharmaceuticals reported a Q4 2025 EPS miss of -9.4% versus consensus, with actual EPS at $-1.31 compared to an estimated $-1.20. The press release contains no financial results or operational updates, only investor conference announcements.

Key Financial Metrics

EPS
−$1.31
est −$1.20 · -9.2%
Revenue
$1.0M
est $1.0M · 0.0%
Rating
miss

Key Facts

  • Reported EPS of $-1.31 missed consensus estimate of $-1.20 by 9.4%, indicating worsening losses.
  • No revenue or operating metrics were disclosed in the release; only investor event schedule was provided.
  • Company announced upcoming presentations at four investor conferences in Q2 2026, but no new clinical or financial data.

Financial Impact

EPS miss of -9.4% implies deteriorating profitability; no revenue details provided

epsnet_loss

Risk Factors

  • Lack of disclosed financials despite labeling as earnings context increases information asymmetry risk
  • Biotech investors may interpret silence on pipeline progress as lack of near-term catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3274427

Track record

19 reports on XENE

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 9h 28m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026